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Abstract
Background: The insulin receptor (INSR) and the insulin growth factor 1 receptor (IGF1R) play important roles in
the etiology of both diabetes mellitus and breast cancer. We aimed to evaluate the expression of hormone and
insulin-related proteins within or related to the PI3K and MAPK pathway in breast tumors of women with or
without diabetes mellitus, treated with or without insulin (analogues).
Methods: Immunohistochemistry was performed on tumor tissue of 312 women with invasive breast cancer, with
or without pre-existing diabetes mellitus, diagnosed in 2000–2010, who were randomly selected from a Danish
breast cancer cohort. Women with diabetes were 2:1 frequency matched by year of birth and age at breast cancer
diagnosis to those without diabetes. Tumor Microarrays were successfully stained for p-ER, EGFR, p-ERK1/2, p-mTOR,
and IGF1R, and scored by a breast pathologist. Associations of expression of these proteins with diabetes, insulin
treatment (human insulin and insulin analogues) and other diabetes medication were evaluated by multivariable
logistic regression adjusting for menopause and BMI; effect modification by menopausal status, BMI, and ER status
was assessed using interactions terms.
Results: We found no significant differences in expression of any of the proteins in breast tumors of women with
(n = 211) and without diabetes (n = 101). Among women with diabetes, insulin use (n = 53) was significantly associated
with higher tumor protein expression of IGF1R (OR = 2.36; 95%CI:1.02–5.52; p = 0.04) and p-mTOR (OR = 2.35; 95%CI:1.
13–4.88; p = 0.02), especially among women treated with insulin analogues. Menopause seemed to modified the
association between insulin and IGF1R expression (p = 0.07); the difference in IGF1R expression was only observed in
tumors of premenopausal women (OR = 5.10; 95%CI:1.36–19.14; p = 0.02). We found no associations between other
types of diabetes medication, such as metformin, and protein expression of the five proteins evaluated.
Conclusions: In our study, breast tumors of women with pre-existing diabetes did not show an altered expression of
selected PI3K/MAPK pathway-related proteins. We observed an association between insulin treatment and increased
p-mTOR and IGF1R expression of breast tumors, especially in premenopausal women. This observation, if confirmed,
might be clinically relevant since the use of IGF1R and mTOR inhibitors are currently investigated in clinical trials.
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Background
Approximately 10% of women diagnosed with breast can-
cer have pre-existing diabetes mellitus, which may affect
their breast cancer progression, prognosis and treatment
options [1–10]. Insulin (and the Insulin Growth Factor
axes) appears to be an important factor linking diabetes
and breast cancer [11–13]. In patients with diabetes, insu-
lin metabolism is altered [14]. Type 2 diabetes is charac-
terized by insulin resistance, and in earlier stages by
hyperinsulinemia (high levels of endogenous insulin).
Women with type 2 diabetes are usually treated with non-
insulin antidiabetic drugs. If women with type 2 diabetes
fail to respond to these glucose-lowering drugs over time,
insulin (analogue) treatment is required. Patients with type
1 diabetes are insulin deficient and therefore rely on
chronic treatment with insulin (analogues) [14].
Two important intracellular signaling pathways in the
regulation of metabolism and cell growth are the phos-
phatidylinositol 3-kinase (PI3K-AKT) and mitogen-
activated protein kinase (MAPK-ERK) [15]. Both path-
ways are involved in tumorigenesis and can be activated
by insulin. Due to the high homology between the two
isoforms of the insulin receptor (INSR-A and INSR-B)
and the insulin growth factor 1 receptor (IGF1R), insulin
can bind to INSR-A, INSR-B and IGF1R [16]. Insulin
analogues are structurally transformed from human in-
sulin and this may result in increased binding affinity to-
wards the IGF1R [17, 18]. Phosphorylation of INSR-B,
caused by insulin binding, preferentially induces meta-
bolic signals via the PI3K pathway, while phosphoryl-
ation of INSR-A and IGF1R by insulin, predominantly
leads to cell growth, and potentially tumor growth, via
activation of the MAPK-ERK pathway [19]. One of the
downstream proteins important for control of cell
growth is mammalian target of rapamycin (mTOR),
which can be activated by the PI3K or MAPK pathway
via respectively extracellular signal-regulated kinases
(ERK) or protein kinase B (AKT) [16].
In vitro and in vivo studies have shown that endogenous
and exogenous insulin can stimulate tumor promotion via
INSR and IGF1R. In vitro, insulin analogue stimulation in-
creases proliferation of breast cancer cells due to en-
hanced IGF1R (and INSR) signaling, while exposure to
human insulin showed low mitogenic potential [20].
Chronic treatment with insulin-like compounds (IGF1, in-
sulin AspB10) with strong binding affinity towards the
IGF1R, decreased the tumor latency time and showed in-
creased MAPK-ERK signaling in a mammary gland mouse
model, while insulin glargine and human insulin treat-
ment did not significantly decrease the time for tumor de-
velopment compared to the vehicle-treated mice [21].
Insulin might also stimulate tumor promotion via
other receptors such as the estrogen receptor (ER) path-
way. There is experimental support that insulin interacts
with estrogens and might stimulate tumor growth via
the ER pathway [13]. Moreover, estrogens enhance insu-
lin signaling by increased expression and/or functional
activity of proteins in the IR/ IGF1R pathway, which
might results in enhanced proliferation [22]. Previous
studies showed that IGF1R expression is higher in
estrogen-dependent cell lines [19].
Little is known about diabetes/insulin exposure and pro-
tein signaling in tumors in the human setting. We hypoth-
esized that tumors of patients with diabetes mellitus have
higher expression of proteins in the insulin signaling path-
way, especially among those treated with insulin and/or
insulin analogues. Specifically, we aimed to evaluate the
expression of (downstream activated) proteins within or
related to the PI3K and MAPK pathways.
Methods
Study design, patient selection and data collection
We conducted a cross-sectional study with a target
population of ~ 300 breast cancer patients, randomly se-
lected from an existing nationwide hospital-based cohort
set up by the Danish Breast Cancer Cooperative Group
(DBCG), of women with primary breast cancer (N =
43,701) diagnosed between 2000 and 2010 [23]. Details
on patient selection and methods of data collection have
been described previously [24]. In short, the selected
women included breast cancer patients with pre-existing
diabetes (exposed) and without diabetes (non-exposed)
sampled as follows: we frequently matched by year of
birth and age at diagnosis (both in 10-year categories)a
random sample of women with diabetes (in strata of
age ≤ 50 and > 50 years at breast cancer diagnosis) to
women without diabetes (Fig. 1) [24]. To allow analyses
of insulin treatment, we included two times as many
women with diabetes as women without diabetes. We
excluded patients with a history of other cancers, non-
invasive or metastasized breast cancer, those treated with
neo-adjuvant therapy, patients with diabetes diagnosed
≤1 year prior to their breast cancer diagnosis, and pa-
tients with no or insufficient tumor tissue. We obtained
data from the DBCG database, linkage with the National
Patient Register in Denmark, linkage with the Danish
Register of Medicinal Products Statistics, and additional
information on height, weight and Body Mass Index
(BMI) prior to breast cancer diagnosis from electronic
medical records [24]. The study protocol was approved
by the Science Ethics Committee of the Region Midtjyl-
land in Denmark (M-20110198).
Diabetes treatment classification
As described also previously [24], we classified diabetes
status based on medical diagnosis from the Danish Na-
tional Patient Register; and diabetes duration as time
from age of diabetes diagnosis till age of breast cancer
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diagnosis. We assigned women with diabetes to a treatment
group if at least 2 prescriptions of an antidiabetic drug were
prescribed in the period up to one year prior to breast can-
cer diagnosis. We defined exposure time as time from age
of start of the antidiabetic drug till age of breast cancer
diagnosis. We classified women with diabetes treated with
insulin only as type 1 diabetes, if they had a recorded diag-
nosis of type 1 diabetes (n = 21), or if a medical code was
missing but they were under age 30 years at diabetes diag-
nosis (n = 4); all other women with diabetes were classified
as type 2. We compared women with diabetes who had a
history of treatment with: insulin (human insulin and/or in-
sulin analogues) vs. never treated with insulin; insulin with
non-insulin antidiabetic drugs vs. insulin only; insulin ana-
logues vs. human insulin only; any antidiabetic medication
vs. diet and exercise only; metformin vs. no metformin. In
the analyses comparing insulin and concomitant non-
insulin antidiabetic drug users vs. insulin only users, we ex-
cluded women who were treated with diet and exercise
only. In the analyses comparing metformin vs. no metfor-
min users, we only included women who had a history of
treatment with non-insulin antidiabetic drugs.
Tumor block collection and immunohistochemical (IHC)
analyses
Formalin-fixed, paraffin embedded tissue samples of the
primary tumors were retrieved from different pathology
departments in Denmark. Morphology, grade, tumor
size, number of positive lymph nodes and clinical tumor
subtype, immunohistochemically defined by ER, PR, and
human epidermal growth factor receptor 2 (HER2) sta-
tus, were available from central pathology review [24].
All formalin-fixed, paraffin embedded tumor blocks of
the primary tumor of each patient were collected, sec-
tioned and hematoxylin and eosin (HE) stained. Two
cores of 2 mm were taken from the most representative
tumor block of each patient for constructing duplicate
Tissue Micro Arrays (TMAs), with one core of each pa-
tient on both TMAs. We chose hormone and insulin-
related proteins within or related to pathways of interest
(MAPK and PI3K) that were previously stained in the
Netherlands Cancer Institute and/or reported in scien-
tific articles with IHC application: p-ER, epidermal
growth factor receptor (EGFR), INSR, IGF1R, p-ERK1/2,
p-mTOR, phospho-ribosomal protein S6 kinase beta-1
Fig. 1 Flow chart of patient identification and selection. Stratified by age at breast cancer diagnosis (≤50 and > 50 years), women with diabetes
were 2:1 frequency-matched on year of birth and age at breast cancer diagnosis (both in 10-year categories) to women without diabetes, to select ~
300 patients with tumor tissue available. ǂ Exact numbers < 5 cannot be shown according to regulations of Statistics Denmark
Bronsveld et al. BMC Cancer  (2018) 18:224 Page 3 of 11
(p-P70S6), and p-AKT. Antibodies for INSR, p-P70S6K,
and p-AKT did not show sufficient validity and reliabil-
ity on human breast tissue; staining was weak or showed
variations in staining pattern. Varying dilutions of these
antibodies and/or staining procedure (manual versus au-
tomated) did not lead to improvement. The antibodies
for p-ER, EGFR, IGF1R, p-ERK1/2, and p-mTOR, were
all developed and validated on human breast tissue by
the Core Facility Molecular Pathology & Biobanking
(CFMPB) of the Netherlands Cancer Institute. For each
antibody a positive control was included.
Immunohistochemistry was performed on a Bench-
Mark Ultra autostainer (Ventana Medical Systems).
Briefly, 3 μm paraffin sections of TMAs were cut using a
microtome, these sections were heated at 75 °C for
28 min, and deparaffinised in the autostainer with ‘EZ
prep’ solution (Ventana Medical Systems). Heat-induced
antigen retrieval was carried out using Cell Conditioning
1 (CC1, Ventana Medical Systems) for respectively 36
(p-mTOR), 64 (p-ERK1/2, EGFR, IGF1R) and 92 (p-ER)
minutes at 95 °C. Primary antibody incubation times
were 16 min (EGFR, IGF1R), 32 min (p-ER) and 1 h (p-
mTOR, p-ERK1/2). Details of the used antibodies, dilu-
tions and localization of staining are summarized in
Additional file 1: Table S1. Bound antibody was detected
using the UltraView Universal DAB Detection Kit (Ven-
tana Medical Systems). Slides were counterstained with
Hematoxylin and Bluing Reagent (Ventana Medical
Systems).
Scoring of the IHC staining was performed by a breast
pathologist (JS). The percentages of stained tumor cells
were assessed for P-ER, EGFR, p-ERK1/2 and p-mTOR
using a 10% step scale (0–100%). However, only the per-
centages of tumor cells stained with moderate to strong
intensity were taken into account. The low intensity stain-
ing was very weak and therefore it was unclear whether
the actual tumor cells or the background was stained. We
aimed to create a binary variable for a positive and nega-
tive staining. The cut-off for ER, PR and HER2 status is
clear from daily practice (http://www.oncoline.nl/borst-
kanker) (< 10% is negative)). However, for none of the
other markers of interest there was a clinically defined
cut-off available and we had to define cut-off values based
on available literature, median expression levels (Add-
itional file 1: Table S2) and advice of an experienced breast
pathologist (JW), before association analyses were carried
out. P-mTOR was considered positive if cytoplasmic stain-
ing was present in ≥40% of the cells. For p-ER and EGFR
was decided on a 10% cut-off for a positive nuclear and re-
spectively membrane staining [25, 26]. P-ERK1/2 was con-
sidered positive if either nuclear or cytoplasmic staining
was present in ≥10% of the cells [27]. IGF1R expression
was scored negative for no staining or weak partial mem-
brane or cytoplasmic staining and was scored positive if
≥10% of the tumor cells had a moderate or strong
complete membrane or cytoplasmic staining [28, 29]. Fig-
ure 2 gives an overview of protein expression patterns of
all proteins that were stained with moderate to strong
staining. For all markers, discordant results between the
two cores of each patient were revised and in case of a dif-
ference, the highest score was used for the analyses. If one
core failed, the value of the remaining core was included
in the analysis. Only the invasive part of the tumor, as
judged by the pathologist, was considered when scoring
the staining. When no (invasive) tumor cells were avail-
able, the result of the staining was coded as a missing
value. Reporting recommendations for Tumor Marker
Prognostic Studies (REMARK) have been followed (Add-
itional file 2: document 1).
Statistical analyses
We hypothesized that diabetes, and in particular insulin
use, would be associated with high(er) expression of
IGF1R/EGFR and downstream activated proteins p-
ERK1/2 and p-mTOR. Our primary analysis was there-
fore to test whether the expression of these proteins in
breast tumors was dependent on diabetes status or insu-
lin use, the latter analysis was restricted to women with
diabetes only. We analyzed these markers as a binary
factor in a multivariable logistic regression model, using
the cut-off value as specified above. For significant find-
ings of continuously scored markers, the proportion of
positively stained tumor cells were analyzed as a con-
tinuous factor using a zero-inflated binomial (ZIB)
model, as the data were not normally distributed. The
ZIB model consists of a count component (negative bi-
nomial) and a binary component (logistic) and gives par-
ameter estimates for both [30]. We did not perform this
analysis for IGF1R since we did not continuously score
the proportion of positively stained tumor for IGF1R.
Potential covariates, i.e. year of breast cancer diagnoses,
age, menopausal status, BMI and diabetes duration, were
individually added to the model and were only included if
the beta-estimate for diabetes or insulin changed > 10%.
Menopause and BMI changed the beta for diabetes with
> 10% in the analyses of p-ER, EGFR, p-mTOR and
IGF1R, and the beta for insulin in the analyses of p-ER,
EGFR and p-ERK1/2. Therefore, for simplicity and
consistency of between marker comparisons, all models
were adjusted for menopause and BMI. Though we had
previously shown that grade, tumor size, and positive
lymph node status were not associated with our outcome
of interest [24], we ran full models including these three
variables to confirm that our conclusions based on statisti-
cally significant findings remained unchanged. For pa-
tients with unknown menopausal status (n = 5), age over
52 years [31] was used as a proxy for postmenopausal sta-
tus. As previously described [24], we imputed missing
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values for BMI (n = 93) using Multivariate Imputations by
Chained Equations (MICE) [32] in R studio with a predict-
ive mean matching regression model for each analyzed
dataset, imputing variables with ascending number of
missing values; number of imputations = 10, number of it-
erations = 25; see (Additional file 1: Table S3). We as-
sumed that data was missing at random and could be
imputed because of correlations with other variables (e.g.
smoking, alcohol, cardiovascular disease, microvascular
disease, income, education, diabetes type, diabetes dur-
ation, height, weight).
Modifications of the associations between diabetes sta-
tus/insulin use and proteins of interest by menopausal
status, BMI and ER status were assessed using interac-
tions terms. To exclude potential bias by the inclusion
of patients with type 1 diabetes we performed a sensitiv-
ity analysis comparing women with type 2 diabetes only
to women without diabetes. We also tested for hetero-
geneity of expression of proteins between tumors of type
1 and type 2 diabetes patients using insulin. A p-value of
< 0.05 was defined as statistically significant. SAS Enter-
prise guide 4.2 for Windows was used for all analyses.
Results
The cross-sectional study consisted of 211 women with
diabetes and 101 women without diabetes, all diagnosed
with breast cancer and with tumor tissue available (Fig. 1).
Patient and breast cancer characteristics at diagnosis have
been published in detail previously and have been summa-
rized in Additional file 1: Table S4 and S5. Most women
with diabetes were categorized as type 2 (88.2%). Immu-
nohistochemistry could be evaluated in 93–96% of breast
tumors, dependent on each marker (Additional file 1:
Table S2). In the evaluated tumors, positive protein ex-
pression was found in 47% for p-ER, 9% for EGFR, 55%
for p-ERK1/2, 59% for p-mTOR and 73% for IGF1R, re-
spectively (Additional file 1: Table S2).
We found no significant differences in tumor expression
of any of the selected proteins between women with and
without diabetes (Fig. 3, Table 1 and Additional file 1:
Table S6). Exclusion of women with type 1 diabetes gave
similar results (Fig. 3, Additional file 1: Table S6 and S7).
We found no effect modification of any of the proteins by
menopause, ER status or BMI). However, because we pre-
viously found that menopause modified the association
between diabetes and breast cancer subtype, we also pre-
sented the results stratified for menopause. After stratifi-
cation for menopause (Fig. 3, Additional file 1: Table S6
Fig. 2 Patterns of immunohistochemical protein expression. a p-ER
nuclear staining (70%), (b). EGFR membrane staining (100%), (c)
p-ERK1/2 nuclear/cytoplasmic staining (100%), (d) p-mTOR cytoplasmic
staining (100%), (e). IGFR strong complete membrane/cytoplasmic
staining (≥10%)
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and S7), we noticed that the direction of the effects of dia-
betes on p-ER, p-ERK1/2 and IGF1R differed in pre- and
postmenopausal women.
Twenty-five percent (n= 53) of the women with diabetes
were treated with insulin, of which 18 combined insulin with
non-insulin antidiabetic drugs (Additional file 1: Table S5).
Among the insulin users, 28 were treated with human insu-
lin only and 25 used insulin analogues with (n= 22) or with-
out human insulin (n = 3). The non-insulin users (75%, n =
158) were treated with non-insulin antidiabetic drugs (n =
74) or diabetes was controlled by diet and exercise only (n =
84). Any insulin use was significantly associated with higher
expression of IGF1R (OR= 2.36; 95%CI:1.02–5.52; p= 0.04)
and p-mTOR (OR= 2.35; 95%CI:1.13–4.88; p= 0.02; Fig. 4,
Table 2 and Additional file 1: Table S8) in breast tumors.
The ORs for IGF1R and p-mTOR additionally adjusted for
grade, tumor size and positive lymph node status were re-
spectively 2.32 (95%CI:1.02–5.30; p = 0.05) and 2.58
(95%CI:0.97–6.81; p = 0.06). Additional analyses including
the proportion of positively stained tumor cells as a con-
tinuous factor (using the ZIB model) gave similar results
(data not shown); e.g. in the analyses for p-mTOR, the
binary components explained most of the difference (esti-
mate = − 1.21, p = 0.02), while the count component did
not add much (estimate = 0.03, p = 0.80). Therefore, the
logistic analyses were appropriate and using the data con-
tinuously did not improve the model. Expression of IGF1R
significantly differed between insulin analogues users (n =
28) and users of human insulin only (n = 25) (Fig. 4,
Additional file 1: Table S8 and S10). Insulin analogue users
more often developed tumors that expressed IGF1R com-
pared to human insulin only users (OR = 4.94;
95%CI:1.11–21.92; p = 0.04). The OR for p-mTOR was
also higher among insulin analogue users, but not signifi-
cantly different (OR = 2.46; 95%CI:0.91–6.63; p = 0.08)
(Fig. 4, Additional file 1: Table S8 and S10).
Menopause seemed to modify the association between
insulin and IGF1R expression (p = 0.07) and the differ-
ence in IGF1R expression between tumors of insulin and
non-insulin users was only observed among premeno-
pausal women with diabetes (OR = 5.10; 95%CI:1.36–
19.14; p = 0.02; Fig. 4, Additional file 1: Table S9 and
S10). The same results were found when we additionally
adjusted for grade, tumor size and positive lymph node
status (OR = 5.08; 95%CI:1.24–20.86; p = 0.02). We
found no significant interaction between insulin use and
ER status (p ≥ 0.15) or BMI (p ≥ 0.20). However, because
the origin of the present breast cancer subtype classification
is largely based on ER status; we confirmed that results
were similar if analyses were stratified by ER-status
(Additional ile 1: Table S9 and S10). Adjustment for ER sta-
tus in the multivariable model did also not materially
change the estimates, but adjustment for breast cancer sub-
type (Luminal A/Luminal B/HER2-positive/triple negative)
Fig. 3 Odds ratios for tumor protein expression status of women with diabetes compared to women without diabetes using logistic regression.
Odds ratios were adjusted for menopause and BMI. For details of the analyses see Table 1 and Additional file 1: Table S7
Table 1 Odds ratios for tumor protein expression status of
women with diabetes compared to women without diabetes
Women with breast cancer
Independent variable of exposure
Diabetes vs. No
Diabetes
Diabetes vs. No Diabetes
Dependent
variablea
crude OR (95%
CI)
P adjusted ORb (95%
CI)
P
p-ER + 0.84 (0.51–1.37) 0.48 1.03 (0.61–1.73) 0.92
EGFR + 1.44 (0.59–3.52) 0.43 1.72 (0.68–4.33) 0.25
p-ERK 1/2 + 0.84 (0.52–1.37) 0.48 0.84 (0.51–1.40) 0.51
p-mTOR + 0.81 (0.49–1.33) 0.40 0.88 (0.52–1.49) 0.64
IGF1R + 0.90 (0.52–1.56) 0.70 0.94 (0.53–1.65) 0.82
aLogistic regression for tumor IHC marker as the dependent variable, with a
negative staining of the tumor marker as reference category. bAdjusted
for menopause (pre/post) at breast cancer diagnosis and BMI closest
measure prior to breast cancer diagnosis (continuous). Women with
diabetes were matched on age at breast cancer diagnosis to women
without diabetes. p-ER Phosphorylated estrogen receptor, EGFR Epidermal
growth = factor receptor, p-ERK Phosphorylated extracellular signal-regulated
kinase, p-mTOR Phosphorylated mechanistic target of rapamycin, IGF1R Insulin
growth factor 1 receptor, OR Odds Ratio, CI Confidence Interval
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led to slightly stronger associations of insulin with IGF1R
(OR = 2.78; 95%CI:1.09–7.09; p = 0.03) and p-mTOR (OR
= 3.42; 95%CI:1.43–8.17; p = 0.006), with more expression
of IGF1R and p-mTOR in triple negative, and less expres-
sion in HER2 positive tumors. We found no significant het-
erogeneity between tumor expression of the proteins of
interest between diabetes type 1 and type 2 insulin users,
except for p-ER (type 1 vs. type 2: OR = 0.28; 95%CI:0.08–
0.95; p = 0.04) (Additional file 1: Table S8 and S10), but
after adjustment for menopause and BMI this difference
was non-significant.
We observed no statistically significant differences be-
tween expression of any of the proteins among tumors
of women with diabetes treated with a combination of
insulin and non-insulin-antidiabetic drugs compared to
insulin-only users, nor did we find differences between
tumors of women with diabetes treated with any dia-
betes medication compared to women with diabetes
treated with diet and exercise only. In our study, 69% (n
= 51) of the women treated with non-insulin antidiabetic
drugs only were treated with metformin (Additional file 1:
Table S5). We did not find a significant decreased effect
of p-mTOR activation in tumors of metformin users (n
= 51) compared to non-insulin antidiabetic drug users
not treated with metformin (n = 23) (OR = 0.57;
95%CI:0.21–1.56; p = 0.27), nor did we find differences
in any of the other proteins.
Discussion
We found no strong evidence that p-ER, EGFR, p-
ERK1/2, p-mTOR, or IGF1R are differently expressed in
breast tumors of women with and without diabetes. We
showed that insulin treatment is associated with higher
IGF1R and p-mTOR tumor expression in women with
diabetes. Among insulin users, IGF1R was significantly
more often expressed in tumors of women treated with
insulin analogues compared to women treated with hu-
man insulin only. We found no strong evidence for an
association between other types of diabetes medication,
such as metformin, and any of the proteins that were
assessed.
Insulin treatment was only associated with IGF1R ex-
pression in tumors of premenopausal women with dia-
betes. We have indications that this difference between
pre- and postmenopausal women is related to hormonal
difference related to tumor subtype because previously,
we found that premenopausal women with breast cancer
and diabetes more often develop tumors that do not ex-
press hormonal receptors (especially among women with
type 1 diabetes) [24]. In ER-negative tumors we see a ten-
dency towards higher IGF1R expression (Additional file 1:
Table S10) and in multiple regression analyses adjusting
for breast cancer subtype it was confirmed that IGF1R
Fig. 4 Odds ratios for tumor protein expression status of women with diabetes treated with insulin compared to women not treated with insulin
using logistic regression. Odds ratios were adjusted for menopause and BMI. For details of the analyses see Table 2 and Additional file 1: Table S10
Table 2 Odds ratios for tumor protein expression status of
women with diabetes treated with insulin compared to women
not treated with insulin
Women with breast cancer and diabetes
Independent variable of exposure
Insulinb vs. No Insulinc Insulinb vs. No Insulinc
Dependent variablea crude OR
(95% CI)
P adjusted ORd
(95% CI)
P
p-ER + 1.13 (0.38–2.19) 0.73 1.08 (0.53–2.19) 0.82
EGFR + 1.84 (0.69–4.91) 0.22 1.67 (0.60–4.67) 0.33
p-ERK 1/2 + 1.31 (0.68–2.53) 0.42 1.24 (0.63–2.44) 0.54
p-mTOR + 2.41 (1.18–4.93) 0.02 2.35 (1.13–4.88) 0.02
IGF1R + 2.47 (1.07–5.67) 0.03 2.36 (1.02–5.52) 0.04
aLogistic regression for tumor IHC marker as the dependent variable, with a
negative staining of the tumor marker as reference category. bWomen with
diabetes treated with insulin (analogues) regardless the use of concomitant
noninsulin antidiabetic drugs. cWomen with diabetes treated only with diet
and exercise and users of noninsulin antidiabetic drugs only. dAdjusted for
menopause (pre/post) at breast cancer diagnosis and BMI closest measure
prior to breast cancer diagnosis (continuous). p-ER Phosphorylated estrogen
receptor, EGFR Epidermal growth = factor receptor, p-ERK Phosphorylated
extracellular signal-regulated kinase, p-mTOR Phosphorylated mechanistic
target of rapamycin, IGF1R Insulin growth factor 1 receptor, OR Odds Ratio, CI
Confidence Interval
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was more expressed in triple negative tumors. This might
indicate that in women with tumors not expressing hor-
mone receptors, the IGF1R signaling pathway might be an
alternative way of breast cancer development, since this
type of tumor is not dependent on the common ER/PR-
signaling. We also found that ER is more often phosphor-
ylated in women using insulin with type 2 diabetes com-
pared to type 1 diabetes, which is in line with our previous
findings that type 2 diabetes insulin users had more often
ER-positive tumors compared to women with type 1 dia-
betes [24]. It has been suggested that phosphorylation of
ER (at Ser118) indicates that the ER signaling pathway in
breast cancer is intact and that it is correlated with re-
sponsiveness of breast cancer to tamoxifen [26]. We did
not find an association between metformin use and p-
mTOR or any other of the examined proteins, while it has
been suggested that metformin can decrease INSR and
IGF1R signaling and can inhibit mTOR [33].
It should be noted that the specific proteins we inves-
tigated, especially IGF1R, are involved in signaling path-
ways that interfere with other growth factor receptor
pathways such as ER, PR and EGFR. Therefore, expres-
sion of these proteins should be interpreted in the con-
text of breast cancer subtype [29]. In our study,
adjustment for ER status did not materially change the
results and adjustment for breast cancer subtype led to
slightly stronger associations of insulin with IGF1R and
p-mTOR. We found no interaction between insulin use
and ER status and we confirmed that results were simi-
lar when analyzed by ER-status.
As far as we know, two previous studies in humans,
with small sample size (n = 39–40), examined protein or
gene expression of the IGF1, IGF2, IGFBP3, INSR,
IGF1R and downstream targets IRS1, IRS2 and mTOR
in women with or without type 2 diabetes [34, 35]. Both
studies found no association between these proteins and
diabetes, which is in line with our findings, except for
IGF1R protein expression that was found to be signifi-
cantly higher in women with diabetes [35]. Since these
studies had no data on insulin treatment among women
with diabetes and the duration and severity of diabetes
might differ between studies, it is hard to explain differ-
ences between their results and ours. In vitro studies
have shown that the PI3K signaling pathway [36–39]
and the MAPK pathway [36, 37] are significantly upreg-
ulated after stimulation of insulin analogues compared
to human insulin. In mammary gland tumors of mice,
expression of IR, IGF1R and p-AKT was significantly
higher in insulin or insulin analogues-treated compared
to vehicle-treated mice, while expression of p-ERK was
only increased among tumors of mice treated with insu-
lin analogues [21]. Our results suggest that treatment
with insulin and insulin analogues increases signaling via
mTOR. However, since the relationship between IGF1R
expression and downstream activation of the m-TOR
pathway is not consistent in pre- and postmenopausal
women, these findings suggest that insulin use may in-
crease p-mTOR independently of increased IGF1R ex-
pression. Since we could not stain p-AKT and the PI3K
and MAPK pathway interacts with many other proteins/
pathways, we can only speculate about the actual signal-
ing pathways involved. .
A strength of our study is that data were collected
from a randomly selected group of women, based on
data of comprehensive Danish biobanks, included medi-
cation history at least 5 years prior to breast cancer diag-
nosis from prescription records. We expect that this
resulted in a patient selection that was minimally af-
fected by several forms of bias, such as survival, selec-
tion or ascertainment bias, as discussed previously [24].
All stainings were validated and performed in one centre
and scored by the same experienced breast pathologist,
to prevent inter-laboratory and inter-observer variability
[40, 41] and to assure quality and completeness of the
data. We scored staining intensity and percentage posi-
tive tumor cells, and used the continuous expression
data to validate our binary analyses. Median expression
levels in our study corresponded with median expression
levels and cut-offs used in previous studies examining
these proteins [25–29]. The percentages of positive
expression for p-ER, EGFR, p-ERK1/2, p-mTOR and
IGF1R were also in line with previous published data,
using similar population selection, IHC methods, and
assessment criteria in primary invasive breast tumors
[26, 27, 29, 35, 42]. Additionally, effects estimates were
adjusted for potential confounders and analyzed for po-
tential effect modifiers and are therefore less likely to be
distorted by the presence of other factors.
We had limited power to study differences of tumor
protein expression among insulin users in women with
type 1 and type 2 diabetes and between insulin ana-
logues users and human insulin only users. Moreover,
the 95% confidence intervals around the presented esti-
mates are wide and might be subject to change. There-
fore we have to interpret both our positive and null
results with caution and we recommend others to con-
firm our findings in a larger dataset.
Another important point that we need to address is
that in patients with type 2 diabetes treatment choices
for the management of diabetes are based on the severity
of the disease. Although diabetes duration did not
change the beta-estimate for diabetes or insulin with >
10% for any of the proteins, we had no power to investi-
gate duration/dose of insulin exposure and the effect on
tumor protein expression. There is a (small) chance that
our findings are subject to confounding by indication;
severe diabetes and not insulin is related with increased
p-mTOR and IGF1R expression. Furthermore, many
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other factors, such as the nutritional/metabolic status
[43, 44] and endogenous insulin levels [45–47] of the pa-
tients, which are interrelated with the severity of dia-
betes and diabetes treatment, might influence mTOR
signaling. Unfortunately, we could not adjust for this in
the analysis since we had no information on the meta-
bolic status and c-peptide levels of the patients.
Altogether, this makes it extremely hard to disentangle
the true association between insulin treatment and
IGF1R/mTOR expression.
Although the majority of insulin users had prescrip-
tions of insulin over several years prior to breast cancer
diagnosis (mean: 8.4 years), we cannot guarantee the se-
quence of events (insulin exposure and subsequent
tumor promotion) because of the potential lag time in
the detection of the tumor. However, tumor size (an im-
portant factor for detection) was not related to diabetes
status or insulin exposure, so it is unlikely that the asso-
ciations we observed were due to reverse causation.
Due to the small frequencies of tumors that expressed
EGFR, we could not interpret the results of this recep-
tor. Unfortunately, antibodies targeting staining of the
INSR and other proteins in the PI3K and MAPK path-
way (such as AKT and p-P70S6K) did not work on our
series of human breast tumor samples, as explained in
the methods. Furthermore, we could not examine the
phosphorylation state of the INSR compared to the
IGF1R since there is only a non-specific p-INSR/p-
IGF1R antibody available yet. BMI was collected from
the medical records of the patients and were incomplete.
However, since we had extensive data on variables corre-
lated with BMI, we were able to impute missing values
using multiple imputations. Although the ratios for ob-
served and imputed BMI were similar, BMI could still be
misclassified for some patients. At last, we considered
that embedding and storage of tissue blocks may have
been different between pathology laboratories, and this
could have affected the results of the staining. However,
this would only have confounded the analyses if diabetes
status or insulin use would have been differentially dis-
tributed between laboratories or years of diagnosis, and
this was not the case (Additional file 3: Figure S1).
Conclusions
We found that insulin treatment in women with diabetes
is associated with p-mTOR tumor expression, and in pre-
menopausal women with IGF1R tumor expression. How-
ever, more research is needed to confirm our findings and
to explore the role of insulin signaling in breast cancer ini-
tiation and/or promotion in patients with diabetes, espe-
cially among those using insulin or insulin analogues. This
observation, if confirmed, might be clinically relevant
since currently the use of IGF1R and mTOR inhibitors are
investigated among breast cancer patients in clinical trials
[19, 48, 49]. IGF1R and mTOR inhibitors might interfere
with glucose metabolism and iatrogenic diabetes has been
reported as side effect of IGF1R inhibitors. Therefore
monitoring for hyperglycemia and dyslipidemia is import-
ant and the use of these inhibitors might be limited in pa-
tients with diabetes [50, 51].
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